Evidence map›Paper›PMID 41267750›Full record

ReviewTheScientificWorldJournal2025

A Review of Novel Cancer Therapeutics and Current Research Trends.

Abimbola Mary Oluwajembola, Suleiman Zakari, Wisdom D Cleanclay, Timothy Ayeni, Adewale Adebosoye, Olayinka S Okoh, Joshua Folamade, Inalegwu Bawa, Olubanke Olujoke Ogunlana

Abstract readReview
In one paragraph

Review in TheScientificWorldJournal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Abimbola Mary OluwajembolaDepartment of Biochemistry, College of Science and Technology, Covenant University, Ota, Ogun State, Nigeria.ORCID https://orcid.org/0000-0002-8626-6015
Suleiman ZakariDepartment of Biochemistry, College of Science and Technology, Covenant University, Ota, Ogun State, Nigeria.ORCID https://orcid.org/0000-0003-2130-0937
Wisdom D CleanclayDepartment of Biochemistry, College of Science and Technology, Covenant University, Ota, Ogun State, Nigeria.
Timothy AyeniDepartment of Biochemistry, College of Science and Technology, Covenant University, Ota, Ogun State, Nigeria.
Adewale AdebosoyeDepartment of Biochemistry, College of Science and Technology, Covenant University, Ota, Ogun State, Nigeria.
Olayinka S OkohDepartment of Chemical Sciences, Faculty of Natural, Health and Applied Sciences, Anchor University, Ayobo, Lagos State, Nigeria.
Joshua FolamadeDepartment of Biochemistry, College of Science and Technology, Covenant University, Ota, Ogun State, Nigeria.
Inalegwu BawaDepartment of Biochemistry, College of Medicine, Federal University of Health Sciences Otukpo, Otukpo, Benue State, Nigeria.
Olubanke Olujoke OgunlanaDepartment of Biochemistry, College of Science and Technology, Covenant University, Ota, Ogun State, Nigeria.ORCID https://orcid.org/0000-0001-5781-592X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The unchecked growth and spread of aberrant cells describe a widely diverse collection of disorders that collectively constitute cancer. Conventional therapies for cancer, including radiation therapy, chemotherapy, and surgery, have increased the chances of survival significantly in most patients. These traditional methods usually result in low tumor or tumor cell specificity, significant systemic toxicity, and the development of drug resistance. This review summarizes updates in cancer therapy, some of which include cutting-edge therapies represented by CAR-T therapy, targeted therapies, gene therapy, arginine-depriving therapy, mitochondria-targeted therapies, neutrophil-targeted therapies, and the latest PROTAC technology for proteolysis-targeting chimera. It has emphasized mechanisms underlying these new therapeutic strategies and their translational potential for treating human cancers. We further discuss, for each approach, the challenges, limitations, side effects, and delivery systems. The review proceeds with a dynamic change in the landscape of cancer research in biology, where machine learning and artificial intelligence are increasingly important to improve our understanding of the mechanisms of cancer and treatment responses. We also describe the potential of stem cell therapy, metabolomics, and novel drug delivery systems toward better patient outcomes. The paper pulls together some of the current research findings and results of clinical trials in new therapeutic developments and emerging areas of research that hold out exciting promises for the future progress of cancer treatment.

Indexed as

NeoplasmsDrug Delivery SystemsGenetic TherapyHumanscancer biologycancer therapeuticsCAR-Temerging therapiesgene therapyPROTAC

Identifiers

PMID41267750
PMCPMC12629702

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.